Delinkage is not a silver bullet and can be politicised this is what is being discussed at the joint World Health Organization and Government of India meeting in New Delhi which is part of an international push led by countries, including India, and backed by NGOs, to slash drug prices.
By undermining a key intellectual property right, the Commission risk worsening the EU’s innovation performance, writes Philip Stevens.
without a more hospitable environment for innovative companies South Africa will stay marooned in its middle-income status. Legislators should therefore view the draft IP bill as an opportunity to turn the ship around.
This WIPO Global Challenges Report describes the innovation process for vaccines. It explains how the restricted availability of vaccines is due to impediments at every stage of the process. Most of these obstacles are manageable, and intellectual property rights are associated with only some of them.
Mexico could benefit from upgraded intellectual property rules to become a regional biotech hub, write Alberto Saracho and Philip Stevens.
Without regulatory data protection, there will be less investment in developing the ground-breaking biomedical treatments of tomorrow.
The delinkage agenda under discussion in Geneva, while well-intentioned, is a distraction from practical solutions to increase access to medicines.
Understanding how exactly these structurally similar molecules work on the human body requires significant investments of time, money and expertise, write Jack Ellis and Philip Stevens.